Orlando, Florida USA (UroToday.com) This phase Ib study tested the feasibility and efficacy of combining apalutamide, an advanced AR blocker, with abiraterone acetate for patients with metastatic castrate-resistant prostate cancer (mCRPC). In 57 mCRPC patients , the investigators found 67% PSA response (≥50%) in androgen axis treatment naïve patients, compared to 15% in the pretreated patients. The most commonly reported adverse reactions were fatigue (42%), diarrhea (21%), and vomiting (21%). Only 1 patient discontinued the study due to grade 3 fatigue.
These results are comparable to the interim analysis from clinical trial NCT01650194, investigating the effect of combination therapy with abiraterone and enzalutamide, in which 76% of the patients had ≥50% PSA decline in a patient population with less metastatic burden. Apalutamide has similar pharmacologic characteristics as enzalutamide, but is thought to have several fold reduced central nervous system permeation. As such, the study results are favorable and the drug combination warrants further investigation.
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new
treatments, enrolling clinical trials, screening and surveillance
recommendations along with updated guidelines. Join us as one of our
subscribers who rely on UroToday as their must-read source for the
latest news and data on drugs. Sign up today for blogs, video
conversations, conference highlights and abstracts from peer-review
publications by disease and condition delivered to your inbox and read
on the go.
First author: Edwin M. Posadas
Citation: J Clin Oncol 35, 2017 (suppl 6S; abstract 173)
at the 2017 Genitourinary Cancers Symposium - February 16 - 18, 2017 – Orlando, Florida USA